gesunheitpfleges.org



Vical 2010 net loss increases to $30.4 million

December 11, 2015

The launch by the company's licensee Merial Limited, the animal health subsidiary of sanofi-aventis, of its ONCEPT?? canine melanoma vaccine, a therapeutic DNA vaccine designed to aid in extending survival of dogs with oral melanoma; and  Approval by the FDA of the Special Protocol Assessment (SPA) agreement for the company's licensee, AnGes MG, Inc., for a Phase 3 clinical trial of its Collategene?? angiogenesis product for patients with advanced peripheral arterial disease (PAD).

Manufacturing Contract

A $2.4 million contract to manufacture plasmid DNA (pDNA) vaccines against HIV for the IPPOX Foundation, a collaborating institution for the Poxvirus Vaccine Regimen Design (PVRD) led by the Centre Hospitalier Universitaire Vaudois (CHUV) under the auspices of the Collaboration for AIDS Vaccine Discovery (CAVD).

Anticipated program highlights for 2011 include:

Data in the first quarter of 2011 from the Phase 1 trial of the company's Vaxfectin?-adjuvanted DNA vaccine for H1N1 influenza;  Database lock in the second half of 2011 in the company's Phase 3 trial of Allovectin-7? in patients with metastatic melanoma;  Initiation in the second half of 2011 of a Phase 3 trial of the company's TransVax?? CMV vaccine candidate for HCT patients; and  Efforts by AnGes to expedite initiation of a multinational Phase 3 clinical trial of its Collategene?? angiogenesis product for patients with advanced PAD.

SOURCE Vical Incorporated